Systematic review: The model for end-stage liver disease - Should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 11-12, 2005, Pages 1079-1089

  Cholongitas, E ^a   Papatheodoridis, G V ^a   Vangeli, M ^a   Terreni, N ^a   Patch, D ^a   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

ACCURACY; ASCITES; BLEEDING; CHILD TURCOTTE PUGH SCORE; CHRONIC LIVER DISEASE; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; HEPATIC ENCEPHALOPATHY; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; LIVER DISEASE; MORTALITY; PERFORMANCE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ASCITES; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 28844473187     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02691.x     Document Type: Review

References (57)

1. Child C, Turcotte J. The liver and portal hypertension. In: Child CI, ed. Surgery and Portal Hypertension. Philadelphia, USA: W. B. Saunders, 1964: 50-8.
2. Pugh R, Murray-lyon I, Dawson J. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
3. Chan CW, Gunsar F, Feudjo M, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005; 21: 217-26.
4. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; (1): CD000551.
5. Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or International Normalized Ratio? Hepatology 1996; 24: 1392-4.
6. Kovacs M, Wong A, MacKinnon K. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994; 71: 727-30.
7. Abad-Lacruz A, Cabre E, Gonzalez-Huix F, et al. Routine tests of renal function, alcoholism, and nutrition improve the prognostic accuracy of Child-Pugh score in nonbleeding advanced cirrhotics. Am J Gastroenterol 1993; 88: 382-7.
8. Cooper G, Bellamy P, Dawson N. A prognostic model for patients with end-stage liver disease. Gastroenterology 1997; 113: 1278-88.
9. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46-52.
10. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? J Hepatol 2004; 41: 344-50.
11. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
12. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
13. Forman L, Lucey M. Predicting the prognosis of chronic liver disease: an evolution from Child to MELD. Hepatology 2001; 33: 473-5.
14. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
15. Cholongitas E, Senzolo M, Triantos C, Samonakis D, Patch D, Burroughs AK. MELD is not enough-enough of MELD? J Hepatol 2005; 42: 475-7.
16. Bajaj JS, Saeian K. MELD score does not discriminate against patients with hepatic encephalopathy. Dig Dis Sci 2005; 50: 753-6.
17. Freeman RB. MELD: the holy grail of organ allocation? J Hepatol 2005; 42: 16-20.
18. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10: 7-15.
19. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-8.
20. Schepke M, Roth F, Fimmers R, et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003; 98: 1167-74.
21. Chalasani N, Clark WS, Martin LG, et al. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 2000; 118: 138-44.
22. Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36: 494-500.
23. Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 2004; 16: 607-12.
24. Salerno F, Merli M, Riggio O, et al Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629-35.
25. Cejna M, Karnel F, Gschwantler M. Child-Pugh vs MELD score to predict survival after TIPS: the Vienna-experience with 349 patients over 10 years. J Hepatol 2002; 36 (Suppl. 1): 16.
26. Angermayr B, Cejna M, Karnel F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52: 879-85.
27. Ferral H, Gamboa P, Postoak DW, et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004; 231: 231-6.
28. Chalasani N, Kahi C, Francois F, et al. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology 2002; 35: 1282-4.
29. Amitrano L, Guardascione MA, Bennato R, Manguso F, Balzano A. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J Hepatol 2005; 42: 820-5.
30. Botta F, Giannini E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European Study. Gut 2003; 52: 134-9.
31. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2.
32. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-8.
33. Giannini E, Bota F, Chiarbonello B. AST/ALT ratio has prognostic value in the assessment of 1-year survival of patients with viral cirrhosis: comparison with MELD and Child-Pugh's score. J Hepatol 2002; 36 (Suppl. 1): 52.
34. Said A, Williams T, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903.
35. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001; 34: 671-6.
36. Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson JP. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int 1998; 54: 518-24.
37. Gunsar F, Raimondo M, Terrani N. Nutritional status and renal function in the prognostic evaluation of cirrhosis; comparison with Pugh's score and MELD. J Hepatol 2002; 36 (Suppl. 1): 53.
38. Angermayr B, Koening F, Cejna M, Karnel F, Gschwantler M, Ferenci P. Creatinine-modified Child-Pugh score (CPSC) compared with MELD-score to predict survival in patients undergoing TIPS. Hepatology 2002; 36: 860A.
39. Giannini E, Botta F, Fumagalli A, et al. Can inclusion of serum creatinine values improve the Child-Turcotte-Pugh score and challenge the prognostic yield of the model for end-stage liver disease score in the short-term prognostic assessment of cirrhotic patients? Liver Int 2004; 24: 465-70.
40. Papatheodoridis GV, Cholongitas E, Dimitriadou E, Touloumi G, Sevastianos V, Archimandritis AJ. MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. World J Gastroenterol 2005; 11: 3099-104.
41. Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Hepatology 2005; 42 (Suppl. 1): 204A.
42. Bzowej N, Huilgol V, Sebanc H, et al. MELD underestimated unless enzymatic creatinine used. J Hepatol 2004; 40 (Suppl. 2): 40.
43. Yoo HY, Edwin D, Thuluvath PJ. Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am J Gastroenterol 2003; 98: 1395-9.
44. Huo TI, Wu JC, Lin HC, et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005; 42: 826-32.
45. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40: 802-10.
46. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32-9.
47. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-43.
48. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-80.
49. Hassanein T, Tofteng F, Brown R, et al. MELD and SOFA scores as a predictor of transplant free survival time in patients with end stage liver disease complicated with intractable hepatic encephalopathy grades 3 and 4. Gastroenterology 2005; 128 (Suppl. 1): A-705.
50. Sheehan M, Zeifer B, Futterer S, Sufit R, Blei A. MELD scores, encephalopathy and survival in acute on chronic liver failure. Gastroenterology 2005; 128: A-705.
51. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005; 42 (Suppl. ): S100-7.
52. Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10: 995-1000.
53. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41: 269-78.
54. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933-53.
55. Kanwal F, Dulai G, Gralnek I, Han S, Spiegel B. The impact of gender on access to liver transplantation in the MELD era. Gastroenterology 2005; 128: A-701.
56. Saab S, Ibrahim AB, Shpaner A, et al. MELD fails to measure quality of life in liver transplant candidates. Liver Transpl 2005; 11: 218-23.
57. Heuman DM, Habib A, Abou-Assi S, Williams L, Mihas A. Rationally derived Child-Turcotte-Pugh (CTP) subclasses permit accurate stratification of near-term risk in cirrhotics patients referred for liver transplantation. Gastroenteroloy 2005; 128: A-734.